NEMUCORE MEDICAL INNOVATIONS, INC.

Biotech · Private

Recombinant human Müllerian Inhibiting Substance (rhMIS) protein therapeutic for ovarian cancer

nemucore.com →
Grants
$225K
1 award
Sector median: 1
Raised
—
No Form D on record
Contracts
—
No federal contracts on record
Patents
14
0 granted · 14 pending
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Federal grantDepartment of Health and Human Services · Phase I · Modified MIS Production & Process Development for Preclinical & Clinical Studies$225,000
Federal grant · SBIR/STTR

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
1691iQure Pharma Inc.—$5.3M
1692MicroMGx, Inc.——
1693AEON RESPIRE, INC.——
1694NEMUCORE MEDICAL INNOVATIONS, INC.——
1695Epigen Biosciences, Inc.——
1696ONECYTE BIOTECHNOLOGIES, INC.——
1697Igenica——

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Patents

USPTO · 0 granted of 14
  • Degradation Of Aurora Kinase (aurk) By Conjugation Of Aurk Inhibitors With E3 Ligase Ligandapplication
  • Platinum Derivatives For Hydrophobic Formulationsapplication
  • Nanoemulsions Of Hydrophobic Platinum Derivativesapplication
  • Therapeutic Nanoemulsion Formulation For The Targeted Delivery Of Docetaxel And Methods Of Making And Using The Sameapplication
  • Image Guided Nanoemulsions For Delivering Therapeutic Agents To The Brain And Methods For Their Preparation And Useapplication
  • Drug Delivery Nanoemulsion Systemsapplication
  • Therapeutic Nanoformulations For Delivery To And Imaging Of The Brain And Methods Of Their Preparation And Use (II)application
  • Nanoemulsion Formulations Of Hydrophobic Platinum Derivatives And Methods Of Their Preparation And Useapplication
  • Drug Delivery System Nanoemulsion Formulationsapplication
  • Platinum Derivatives For Hydrophobic Formulations And Preparation And Uses Thereofapplication
  • Multifunctional Nanoemulsions For Therapyapplication
  • Degradation Of Aurora Kinase (aurk) By Conjugation Of Aurk Inhibitors With E3 Ligase Ligandapplication

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.